Poway, CA (PRWEB) January 18, 2016 -- Dr. Bob Harman, CEO for VetStem Biopharma, was asked by the editors, the top regenerative medicine luminaries in human medicine, to write two key chapters to share the advances made in veterinary medicine with stem cell therapy. “I am honored to have been asked to contribute to such an important book,” said Dr Harman. “This information will help human stem cell companies with their quest to get products through the regulatory and research hurdles and on the market and helping patients.”
Dr. Harman has been a leader in this area for over a decade and has presented at dozens of human regenerative medicine conferences. He pulls from his biotechnology and veterinary experience to perfect the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. VetStem is leading in the development for regenerative medicine in the veterinary field, with over 11,000 animals treated in the last 12 years. Dr. Harman is also author on 13 peer-reviewed articles and book chapters.
The book, entitled Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies, is a unique guide to emerging stem cell technologies and the opportunities for their commercialization. It provides in-depth analyses of the science, business, legal, and financing fundamentals of stem cell technologies, offering a holistic assessment of this emerging and dynamic segment of the field of regenerative medicine. The book includes reviews of the very latest advances in the technology and business of stem cells used for therapy, research, and diagnostics. It identifies key challenges to the commercialization of stem cell technology and avenues to overcome problems in the pipeline. Dr Harman’s chapters cover the market for stem cell medicines for domestic and high value animals and practical approaches to stem cell medicine in the veterinary field.
The book is written by an expert team with extensive experience in the business of the applied science of stem cell research. This comprehensive volume is essential reading for researchers in cell biology, biotechnology, regenerative medicine, and tissue engineering, including scientists and professionals, looking to enter commercial biotechnology fields.
About VetStem Biopharma
VetStem Biopharma, was founded by Dr Bob Harman and is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and over 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.
Kristi Hauta, VetStem Biopharma, http://www.vet-stem.com/, +1 858-748-2004 Ext: 208, [email protected]
SOURCE VetStem Biopharma